Hyperglycaemia (Non Diabetic), Prediabetes
Conditions
Keywords
Lean pork, Muscle Protein Synthesis, Protein, Plant-Based
Brief summary
We will be directly comparing a high-quality protein diet composed primarily of lean pork loin (PORK) to a lower-quality plant-based protein diet (PLANT) in individuals with prediabetes on muscle and whole-body protein turnover and glucose regulation.
Interventions
OTHERLean Pork vs Plant-Based Protein
Participants will eat prepared study meals for three days that have either protein sourced from lean pork or plant-based sources.
Sponsors
University of Arkansas
National Pork Board
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
40 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
* 1\. Males and females ages 40-65 years. * 2\. BMI 25 to ≤40 kg/m2 (or body fat % ≥25% in males or ≥36% in females) * 3\. Capable of providing informed consent. * 4\. COVID-19 negative and/or asymptomatic. * 5\. Willing to abstain from drinking alcohol or consuming marijuana and CBD products during the 4-day study meal period * 6\. HbA1c: 5.7-6.4% or fasting glucose 100-125 mg/dL
Exclusion criteria
* 1\. Participant who does not/will not eat animal protein sources. * 2\. Allergy to wheat, soy, or common ingredients in plant-based protein products. * 3\. Body mass index \<25 kg/m2 or \>40 kg/m2. * 4\. Hemoglobin \<10g/dL at screening. * 5\. Platelets \<150,000/uL at screening. * 6\. History of chemotherapy or radiation therapy for cancer in the 6 months prior to enrollment. * 7\. History of gastrointestinal bypass/reduction surgery. * 8\. Pregnant or lactating individuals. * 9\. History of a chronic inflammatory disease (e.g. Lupus, Crohn's disease) * 10\. Currently receiving androgen (e.g., testosterone) or anabolic (e.g., GH, IGF-I) therapy. * 11\. Currently using prescription blood thinning medications. * 12\. Currently using corticosteroid medications (cortisone, hydrocortisone, prednisone, etc.). * 13\. Unable or unwilling to suspend aspirin use for 7 days prior to Visit 3 and Visit 7. * 14\. Unwilling to avoid using protein or amino-acid supplements during participation. * 15\. Unwilling to fast overnight. * 16\. Unwilling to avoid alcohol, marijuana and CBD products for the four study days. * 17\. Participants on glucagon-like-peptide-1 receptor agonist (GLP-1-RA) medications for \<1 month or with less than one treatment dose (injection) every two weeks
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Muscle Protein Synthesis | 24 hours | Mixed muscle protein synthesis expressed as the fractional synthetic rate. |
| Whole Body Protein Balance | 24 hours | Amount of net protein gained per unit of time. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Whole Body Protein Synthesis | 24 hours | Amount of protein produced per unit of time. |
| 24-hour Mean Glucose | 24 hours | Derived from continous glucose monitor data. |
Countries
United States
Contacts
CONTACTDavid Church, PhD
CONTACTAmanda Gwin, PA-C
PRINCIPAL_INVESTIGATORDavid Church, PhD
University of Arkansas
Outcome results
None listed